Pictet Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Pictet Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-426,821	Closed	-$7.56M	–	2150
2026 Q1	$7.56M	Buy	426,821 +35,937	+9%	+$774K	0.01%	706
2025 Q4	$9.84M	Buy	390,884 +27,434	+8%	+$644K	0.01%	675
2025 Q3	$8.23M	Buy	363,450 +15,101	+4%	+$352K	0.01%	711
2025 Q2	$6.07M	Buy	348,349 +33,507	+11%	+$620K	0.01%	755
2025 Q1	$7.62M	Sell	314,842 -33,012	-9%	-$912K	0.01%	724
2024 Q4	$11.1M	Buy	347,854 +49,901	+17%	+$1.5M	0.01%	635
2024 Q3	$8.77M	Buy	297,953 +44,905	+18%	+$1.66M	0.01%	686
2024 Q2	$9.71M	Sell	253,048 -820,186	-76%	-$37.1M	0.01%	634
2024 Q1	$63M	Sell	1,073,234 -271,329	-20%	-$17.3M	0.07%	268
2023 Q4	$80.5M	Buy	1,344,563 +610,413	+83%	+$31M	0.09%	236
2023 Q3	$27.9M	Buy	+734,150	New	+$32.2M	0.03%	389

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Pictet Asset Management's APLS Position: Q2 2026 in Review

Pictet Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 426,821 shares — an estimated $7.56M sold.

Pictet Asset Management first reported a position in APLS in Q3 2023 and held it in 11 quarters. The position peaked at $80.5M in Q4 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Pictet Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Pictet Asset Management sold 426,821 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.56M.
Pictet Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 11 quarters.
Pictet Asset Management's Apellis Pharmaceuticals position peaked at $80.5M in Q4 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.